Neoadjuvant combination checkpoint blockade trial yields high response rates for patients with high-risk stage three melanoma

(University of Texas M. D. Anderson Cancer Center) Combination checkpoint blockade before surgery (neoadjuvant therapy) produced a high response rate among patients with high-risk stage three melanoma, with nearly half having no sign of disease at surgery, but a high incidence of side effects caused the trial to be closed early.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news